Literature DB >> 24222609

Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".

Laura Morata1, Josep Mensa, Alex Soriano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24222609      PMCID： PMC3837855          DOI： 10.1128/AAC.01587-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  19 in total

1.  Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient.

Authors:  Fabio Arena; Tommaso Giani; Angelo Galano; Marcello Pasculli; Valeria Peccianti; Maria Iris Cassetta; Andrea Novelli; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

2.  Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.

Authors:  Irma Hoyo; Juan Martínez-Pastor; Sebastian Garcia-Ramiro; Consuelo Climent; Mercé Brunet; Marta Cuesta; Josep Mensa; Alex Soriano
Journal:  Scand J Infect Dis       Date:  2012-03-04

3.  Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.

Authors:  Kazuaki Matsumoto; Ayumi Takeshita; Kazuro Ikawa; Akari Shigemi; Keiko Yaji; Yoshihiro Shimodozono; Norifumi Morikawa; Yasuo Takeda; Katsushi Yamada
Journal:  Int J Antimicrob Agents       Date:  2010-04-13       Impact factor: 5.283

4.  Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

Authors:  Federico Pea; Mario Furlanut; Piergiorgio Cojutti; Francesco Cristini; Eleonora Zamparini; Loretta Franceschi; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

5.  Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.

Authors:  Yasuhiro Tsuji; Yoichi Hiraki; Kana Matsumoto; Akiko Mizoguchi; Tsutomu Kobayashi; Shinichi Sadoh; Kunihiko Morita; Hidetoshi Kamimura; Yoshiharu Karube
Journal:  J Infect Chemother       Date:  2010-06-26       Impact factor: 2.211

Review 6.  Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature.

Authors:  Katie M Muzevich; Kimberly B Lee
Journal:  Ann Pharmacother       Date:  2013-05-14       Impact factor: 3.154

7.  Cefepime versus cefpirome: the importance of creatinine clearance.

Authors:  Jeffrey Lipman; Steven C Wallis; Robert J Boots
Journal:  Anesth Analg       Date:  2003-10       Impact factor: 5.108

8.  Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Authors:  Craig R Rayner; Alan Forrest; Alison K Meagher; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Risk factors for a low linezolid trough plasma concentration in acute infections.

Authors:  Laura Morata; Marta Cuesta; Jhon F Rojas; Sebastian Rodriguez; Merce Brunet; Gregori Casals; Nazareth Cobos; Cristina Hernandez; José A Martínez; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.

Authors:  Federico Pea; Elena Di Qual; Aldo Cusenza; Loris Brollo; Marco Baldassarre; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.